Tislelizumab Production Cost Reports

The report provides a detailed analysis essential for establishing a tislelizumab production plant. It encompasses all critical aspects necessary for tislelizumab production, including the cost of tislelizumab production, tislelizumab plant cost, tislelizumab production costs, and the overall tislelizumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a tislelizumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Tislelizumab is an immunotherapy drug that targets the PD-1 protein on T-cells. It prevents cancer cells from hiding behind PD-L1 interactions and thereby boosts the immune system's ability to attack tumours. It is approved for treating advanced or metastatic cancers like oesophageal squamous cell carcinoma (ESCC) in patients who've progressed after prior chemotherapy.

It is used as a first-line HER2-negative gastric or gastroesophageal junction adenocarcinoma with chemotherapy if PD-L1 positive. It is utilized in non-small cell lung cancers either as monotherapy or combined with platinum-based chemo, extensive-stage small cell lung cancer (SCLC). It shows superior overall survival and progression-free survival benefits in these indications compared to standards like paclitaxel or docetaxel.

The market for tislelizumab is influenced by global cancer incidence, mainly in lung, oesophageal, gastric, and Hodgkin lymphoma. Its FDA approval for advanced oesophageal squamous cell carcinoma and preference over other pembrolizumab contribute to its market demand. The combination therapy expansions, cost-competitive pricing, government reimbursement support, etc. fuels its market.

The high biologic production costs pressuring payers under value-based models, hospital-centric infusion distribution with vial preferences, and regulatory factors for biosimilar entry post-patent impact industrial tislelizumab procurement. Other factors like supply chain reliance on major companies because of API shortages, regional disparities, and bulk purchasing dynamics favouring stable cold-chain logistics impact its sourcing costs.

Raw Material for Tislelizumab Production

According to the tislelizumab production plant project report, the key raw materials used in the production of tislelizumab include Chinese hamster ovary (CHO) cell line, serum-free cell culture media, and buffers.

Production Process of Tislelizumab

The extensive tislelizumab production cost report consists of the following major industrial production process:

1. From CHO cell line: The production process of tislelizumab uses Chinese hamster ovary (CHO) cells grown in serum-free suspension culture. The process involves sequential cell expansion passages, secretion of the antibody into the medium, and harvest by filtration to remove cell debris. The multi-step purification, including chromatography, virus inactivation, and virus retention filtration, to yield tislelizumab. The drug product is then formulated by thawing, bioburden filtration, sterile filtration, filling into vials, and inspection.

Tislelizumab is a humanised IgG4 monoclonal antibody with a molecular formula of C6410H9916N1686O2009S40 and a mass of around 143935 Da. It is engineered with specific Fc mutations (S228P, L234A, L235A, P329G) to minimise Fcγ receptor binding while maximising PD-1 blockade. It appears as a clear to slightly opalescent, colourless to slightly yellowish concentrate for IV infusion. It has a steady-state volume of distribution of 6.42 L, typical for monoclonal antibodies, limited tissue penetration, and degradation via catabolic pathways into peptides and amino acids. It has in-use chemical and physical stability up to 10 days at 2-8 °C after dilution.